Home > Insider Trading > Filing (0001181431-13-037300)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070081	Ptc Therapeutics Inc.	PTCT	Pharmaceutical Preparations (2834)	043416587

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578965	Adam Koppel	C/O Brookisde Capital Management, Llc John Hancock Tower, 200 Clarendon St. Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-06-25	1,083,333	$0.00	1,083,333	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2013-06-25	1,250,000	$15.00	2,333,333	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Four Senior Preferred Stock	Acquisiton	2013-03-07	1,083,333	$12.00	1,083,333	$0.00
Common Stock	Series Four Senior Preferred Stock	Disposition	2013-06-25	1,083,333	$0.00	1,083,333	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,083,333			No	4	A	Indirect
0			No	4	C	Indirect

Footnotes

All outstanding shares of Series Four Senior Preferred Stock were automatically converted into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration.
Dr. Adam Koppel is a Managing Director of Brookside Capital Management, LLC ("BCM"). BCM is the sole general partner of Brookside Capital Investors, L.P. ("BCI"), which is the general partner of Brookside Capital Partners Fund, L.P. ("BCP Fund"). By virtue of these relationships, Dr. Koppel may be deemed to beneficially own the securities held by the BCP Fund. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
BCM is also the sole general partner of Brookside Capital Investors II, L.P. ("BCI II"). BCI II is the sole general partner of Brookside Capital Trading Fund, L.P. ("BCT Fund"). By virtue of these relationships, Dr. Koppel may be deemed to beneficially own the securities held by the BCT Fund. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.